Inhibition of cervical cancer cell growth in vitro and in vivo with dual shRNAs
Authors:
- 19 November 2010
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 18 (3) , 219-227
Abstract
RNA interference (RNAi)-based gene silencing is widely used in laboratories for gene function studies and also holds a great promise for developing treatments for diseases. However, in vivo delivery of RNAi therapy remains a key issue. Lentiviral vectors have been employed for stable gene transfer and gene therapy and therefore are expected to deliver a stable and durable RNAi therapy. But this does not seem to be true in some disease models. Here, we showed that lentivirus delivered short-hairpin RNA (shRNA) against human papillomavirus (HPV) E6/E7 oncogenes were effective for only 2 weeks in a cervical cancer model. However, using this vector to carry two copies of the same shRNA or two shRNAs targeting at two different but closely related genes (HPV E6 and vascular endothelial growth factor) was more effective at silencing the gene targets and inhibiting cell or even tumor growth than their single shRNA counterparts. The cancer cells treated with dual shRNA were also more sensitive to chemotherapeutic drugs than single shRNA-treated cells. These results suggest that a multi-shRNA strategy may be a more attractive approach for developing an RNAi therapy for this cancer.Keywords
This publication has 41 references indexed in Scilit:
- Delivery Vehicles for Small Interfering RNA In VivoHuman Gene Therapy, 2008
- Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenesCancer Gene Therapy, 2006
- RNA Interference against Human Papillomavirus Oncogenes in Cervical Cancer Cells Results in Increased Sensitivity to CisplatinMolecular Pharmacology, 2005
- Inhibition of respiratory viruses by nasally administered siRNANature Medicine, 2004
- Using RNAi to catch Drosophila genes in a web of interactions: insights into cancer researchOncogene, 2004
- Unlocking the potential of the human genome with RNA interferenceNature, 2004
- siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cellsOncogene, 2003
- Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interferenceOncogene, 2002
- Modulation of HIV-1 replication by RNA interferenceNature, 2002
- Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathwaysProceedings of the National Academy of Sciences, 2000